Mochida Launches Teriparatide Biosimilar for the Treatment of Osteoporosis in Japan
Shots:
- Mochida launched “Teriparatide BS subcutaneous injection Kit 600μg MOCHIDA” as it has been listed on the NIH reimbursement price list
- The launch will improve QoL and lead to the reduction of the financial burden of patients with osteoporosis. The teriparatide biosimilar has developed in collaboration with Gedeon Richter
- Teriparatide BS Injection Kit 600μg is a novel biosimilar approved in Japan targeted for osteoporosis with a recommended dose of 20 μg SC once a day that enhances bone formation and improves bone structure. It is a disposable kit preparation with the delivery device and available for self-injection
Click here to read full press release/ article | Ref: Mochida | Image: Mochida
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com